Dementias Platform UK (@dementiasplatform.bsky.social)

🧠 The NTAD study has demonstrated that MEG brain scanning technology can reliably detect Alzheimer's disease and monitor changes over time. This research by Yasir Widatalla and Cara Alcock could transform how we develop treatments by making clinical trials more efficient and precise. zurl.co/tgG2m

loading . . .

NTAD - Journey The New Therapeutics in Alzheimer's disease study (NTAD for short) has been running for several years. There is still an urgent need for better diagnosis and treatment for dementia. One problem is that clinical trials have just been too slow, expensive and uncertain. NTAD has been looking at a way that can reduce the cost, risk and time it takes to get safe and effective new drugs. Our main research has been to test a new type of brain scanner called MEG, to see if it can pick up the effect of Alzheimer's over time on brain health. Nearly 150 people have taken part in the NTAD study which has shown that the MEG scan works in detecting Alzheimer's disease, and changes over a year, person by person. A critical step was to show that MEG scans give the same result every time, called reliability. This is needed, to detect the benefit from a new drug. Here Yasir Widatalla and Cara Alcock describe how the study was delivered. https://zurl.co/tgG2m